Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757531 · ClinicalTrials.gov registry record · Phase 1
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05757531 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants.
The verdict
NCT05757531, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air. The study will last up to approximately 15 weeks including the screening period of 28 days.
Interventions
- DRUG [¹⁴C]-LY3437943
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05757531
The ClinicalTrials.gov registry entry for NCT05757531 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [¹⁴C]-LY3437943 is the first listed.
NCT05757531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05757531 about?
NCT05757531 is a clinical study titled "A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants". The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be ...
What is the current status of trial NCT05757531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-03-17. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT05757531?
The interventions under investigation include: [¹⁴C]-LY3437943 (DRUG).
Who is sponsoring clinical trial NCT05757531?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.